From the Department of Neurology (Y.H., M.A.W., J.E.A.W., S.M.P., E.S., S.L.C.), Department of Ophthalmology and Visual Sciences (J.E.A.W.), Department of Radiology (T.R., K.L.S.), University of Utah; and George E. Wahlen Veterans Affairs Medical Center (S.L.C.), Salt Lake City, UT.
Neurology. 2023 Oct 3;101(14):e1478-e1482. doi: 10.1212/WNL.0000000000207590. Epub 2023 Jul 17.
ATX-FGF14 (formerly spinocerebellar ataxia 27, OMIM #193003) is an autosomal dominant condition caused by a pathogenic variant in the fibroblast growth factor 14 (, OMIM #601515) gene located on chromosome 13. The phenotypic expression can vary in patients with the same genotype, often delaying diagnosis, especially in probands without known affected relatives and/or with limited available family history. We describe 2 cases of ATX-FGF14 in 1 family with a focus on the importance of differentiating episodic manifestations of neurogenetic conditions from inflammatory/autoimmune neurologic conditions. A 68-year-old male patient (case 1) presented with episodic dysarthria, dizziness, imbalance, and encephalopathy, creating suspicion for a possible autoimmune etiology. At the first evaluation, the patient reported no significant family history. Four years later, on revisiting the family history, he noted that his 49-year-old niece (case 2) had also developed neurologic symptoms of an unclear etiology. On evaluation, she had tremor and ataxia. Both patients also had coexistent evidence of systemic autoimmunity that likely contributed to the initial suspicion of neurologic autoimmunity, and neither had cerebellar or brainstem volume loss. Ultimately, their genetic testing revealed a pathogenic structural variant in the gene, consistent with ATX-FGF14. These 2 cases highlight the importance of a detailed interval family history at each visit, especially in undiagnosed adult patients, as well as the importance of objectively analyzing the impact of immunotherapy diagnostic treatment trials to avoid unnecessary immunomodulatory medications.
ATX-FGF14(原称脊髓小脑共济失调 27,OMIM #193003)是一种常染色体显性遗传疾病,由位于 13 号染色体上的成纤维细胞生长因子 14(,OMIM #601515)基因的致病性变异引起。具有相同基因型的患者表型表达可能存在差异,这常常导致诊断延迟,尤其是在无已知受累亲属和/或可获得的家族史有限的先证者中。我们描述了一个家族中的 2 例 ATX-FGF14 病例,重点介绍了将神经遗传疾病的发作表现与炎症/自身免疫性神经系统疾病区分开来的重要性。一位 68 岁的男性患者(病例 1)表现为发作性构音障碍、头晕、失衡和脑病,这引发了对可能的自身免疫病因的怀疑。在首次评估时,患者报告无明显家族史。4 年后,在重新询问家族史时,他指出他 49 岁的侄女(病例 2)也出现了不明病因的神经系统症状。在评估时,她有震颤和共济失调。两位患者也同时存在系统性自身免疫的证据,这可能导致最初对神经系统自身免疫的怀疑,而且他们均没有小脑或脑干体积损失。最终,他们的基因检测显示基因存在致病性结构变异,符合 ATX-FGF14。这两个病例强调了在每次就诊时详细询问间隔期家族史的重要性,尤其是在未确诊的成年患者中,以及客观分析免疫治疗诊断性治疗试验的影响以避免不必要的免疫调节药物的重要性。